### ğŸ¦¶ Peripheral Artery Disease: Supervised Exercise Training

#### âœ… True Statements
1. **Supervised exercise training** is recommended as initial therapy for patients with **intermittent claudication** due to **peripheral artery disease (PAD)**.
2. **Supervised exercise training** improves **functional performance**, **maximal walking distance**, and **initial claudication distance** more effectively than **home exercise**, although **quality of life** may not differ.
3. If supervised exercise training is not available, **home-based exercise training** is an appropriate alternative.
4. **Medical therapy and exercise training** are the primary treatments for **chronic claudication**, with **revascularization** reserved for cases in which these treatments fail.
5. **Cilostazol** is a **phosphodiesterase inhibitor** with **antiplatelet and vasodilator activity** that increases **pain-free walking distance** and **overall walking distance** in patients with claudication.
6. **Cilostazol** is contraindicated in patients with **heart failure with reduced ejection fraction (HFrEF)**.
7. **Pentoxifylline** is **ineffective** in treating **peripheral artery disease** and should not be used.

#### ğŸ’¬ Extra
1. This recommendation aligns with American College of Cardiology/American Heart Association guidelines.
2. Meta-analyses show that supervised exercise improves walking distances more than home exercise.
4. This patient presents with **lifestyle-limiting intermittent claudication** but no evidence of **critical limb ischemia**, supporting conservative treatment.
5. Cilostazol is a reasonable pharmacologic adjunct in patients without contraindications.
6. The **FDA black box warning** on cilostazol applies to all patients with **known heart failure**, including those with HFrEF.
7. Although FDA-approved, pentoxifylline is inferior to cilostazol and exercise therapy.

#### ğŸ“‡ Tags
#PeripheralArteryDisease #IntermittentClaudication #SupervisedExercise #Cilostazol #HFrEF #PAD #Revascularization #Pentoxifylline

#### ğŸ“š Reference
Jansen SC, Abaraogu UO, Lauret GJ, et al. Modes of exercise training for intermittent claudication. *Cochrane Database Syst Rev*. 2020;8:CD009638. PMID: 32829481 doi:10.1002/14651858.CD009638.pub3

#### ğŸ†” Question ID
CVMCQ24056

#### ğŸ•’ Last Updated
January 2025

---

#### ğŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Peripheral Artery Disease, Medical Therapy for Peripheral Artery Disease

---

### ğŸ“˜ Related Text Derivations

#### âœ… True Statements
1. In patients who can exercise, **supervised exercise training** is recommended for **intermittent claudication** and is associated with **improved functional performance**.
2. **Supervised exercise** improves **maximal walking distance** and **initial claudication distance** more than **home exercise**, although **quality of life** does not differ significantly.
3. A **therapeutic trial of cilostazol** should be considered in patients with claudication.
4. **Cilostazol** has an **FDA black box warning** and should not be used in patients with **heart failure**.
5. **Pentoxifylline** is **ineffective** for peripheral artery disease and **should not be used**.
6. There is **no approved pharmacotherapy** for patients with **chronic limb-threatening ischemia (CLTI)**.

#### ğŸ’¬ Extra
1. Supervised programs are often conducted in medical centers or rehabilitation settings.
2. Multiple trials have shown superior physical performance metrics with supervised exercise, but not necessarily better patient-reported outcomes.
3. Cilostazol acts through **vasodilation** and **antiplatelet effects**, improving walking ability.
4. This warning is similar to other phosphodiesterase inhibitors such as **milrinone**.
6. Patients with CLTI are instead managed with **revascularization** or other **limb salvage** strategies.

#### ğŸ·ï¸ Tags
#PAD #IntermittentClaudication #SupervisedExercise #Cilostazol #Pentoxifylline #CLTI #PeripheralArteryDisease
